Stay updated with breaking news from Molly cogan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat. ....
First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received. ....